Is Farxiga FDA approved?

Is Farxiga FDA approved?

Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.

When was Farxiga approved by FDA?

to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors….Development Timeline for Farxiga.

Date Article
Jan 8, 2014 Approval FDA Approves Farxiga to Treat Type 2 Diabetes

Is Farxiga being recalled?

To date, the FDA has yet to recall Farxiga in the United States or worldwide.

How much does Farxiga cost in USA?

The cost for Farxiga oral tablet 5 mg is around $566 for a supply of 30 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. Farxiga is available as a brand name drug only, a generic version is not yet available.

Is Farxiga good for kidneys?

In August 2020, results from the DAPA-CKD Phase III trial demonstrated that Farxiga achieved unprecedented reduction in the composite risk of kidney failure and CV or renal death in patients with CKD with and without T2D versus placebo.

What happens if you stop taking forxiga?

Do not stop taking dapagliflozin without talking to your doctor first. If you stop taking it suddenly, your diabetes may get worse. If this medicine is not working for you or you’re bothered by side effects, speak to your doctor. They may be able to recommend another medicine to treat your diabetes.

Is there a cheaper alternative to Farxiga?

There are currently no generic alternatives to Farxiga.

When was Farxiga first approved by the FDA?

Farxiga Approval History. FDA Approved: Yes (First approved January 8, 2014) Brand name: Farxiga. Generic name: dapagliflozin. Dosage form: Tablets. Company: AstraZeneca. Treatment for: Diabetes, Type 2. Farxiga (dapagliflozin) is a selective sodium-glucose cotransporter-2 inhibitor for the treatment of adults with type 2 diabetes mellitus.

When was far-see-GA approved by the FDA?

Monday, 13 January 2014. AstraZeneca and Bristol-Myers Squibb Company announced the US Food and Drug Administration (FDA) approved FARXIGA™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

How is Farxiga used in the treatment of diabetes?

Farxiga (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. as an adjunct to diet and exercise to improve glycemic control in adults.

How many clinical trials are there for Farxiga?

Farxiga has a robust programme of clinical trials that includes more than 35 completed and ongoing Phase IIb/III trials in more than 35,000 patients, as well as more than 2.5 million patient-years’ experience.

About the Author

You may also like these